Michael Lee Milligan net worth and biography

Michael Milligan Biography and Net Worth

Insider of Neumora Therapeutics

Michael Milligan is Neumora’s Chief Financial Officer. He joined Neumora as Senior Vice President of Finance and Principal Accounting Officer in December 2021, where he played a crucial role in guiding Neumora through its financial milestones, including the Company’s successful IPO in 2023. Previously, he served as Vice President of Finance and Corporate Controller at Y-Mabs Therapeutics, Inc. Prior to this, he served as Vice President of Finance and Corporate Controller at Acorda Therapeutics, Inc., Executive Vice President and Chief Financial Officer at New Haven Pharmaceuticals, Inc., and Vice President and Chief Accounting Officer at Shionogi, Inc. He began his career in public accounting at KPMG LLP and Ernst & Young LLP. Mr. Milligan holds a Bachelor of Business Administration with a concentration in Accounting from the University of Miami and a Master of Business Administration from Georgia State University. Mr. Milligan is a Certified Public Accountant.

What is Michael Lee Milligan's net worth?: The estimated net worth of Michael Lee Milligan is at least $46.70 thousand as of February 17th, 2026. Milligan owns 21,034 shares of Neumora Therapeutics stock worth more than $46,695 as of April 27th. This net worth estimate does not reflect any other investments that Milligan may own. Learn More about Michael Lee Milligan's net worth.
How do I contact Michael Lee Milligan?: The corporate mailing address for Milligan and other Neumora Therapeutics executives is , , . Neumora Therapeutics can also be reached via phone at 857-760-0900 and via email at [email protected]. Learn More on Michael Lee Milligan's contact information.
Has Michael Lee Milligan been buying or selling shares of Neumora Therapeutics?: Michael Lee Milligan has not been actively trading shares of Neumora Therapeutics during the past quarter. Most recently, Michael Lee Milligan sold 1,436 shares of the business's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $3.56, for a transaction totalling $5,112.16. Following the completion of the sale, the insider now directly owns 21,034 shares of the company's stock, valued at $74,881.04. Learn More on Michael Lee Milligan's trading history.
Who are Neumora Therapeutics' active insiders?: Neumora Therapeutics' insider roster includes Paul Berns (Insider), Kristina Burow (Director), Matthew Fust (Director), Michael Milligan (Insider), and Joshua Pinto (President). Learn More on Neumora Therapeutics' active insiders.
Are insiders buying or selling shares of Neumora Therapeutics?: In the last twelve months, Neumora Therapeutics insiders bought shares 2 times. They purchased a total of 3,831,400 shares worth more than $9,999,954.00. In the last twelve months, insiders at the sold shares 5 times. They sold a total of 138,090 shares worth more than $390,051.47. The most recent insider tranaction occured on February, 17th when insider Daljit Singh Aurora sold 6,165 shares worth more than $21,947.40. Insiders at Neumora Therapeutics own 26.8% of the company. Learn More about insider trades at Neumora Therapeutics.
Information on this page was last updated on 2/17/2026.

Michael Lee Milligan Insider Trading History at Neumora Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/17/2026	Sell	1,436	$3.56	$5,112.16	21,034
2/18/2025	Sell	1,978	$1.69	$3,342.82	22,470

Michael Lee Milligan Buying and Selling Activity at Neumora Therapeutics

Neumora Therapeutics Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $2.22

$2.18

$2.31

50 Day Range

MA: $2.67

$1.93

$3.59

2 Week Range

Now: $2.22

$0.61

$3.65

Volume

952,960 shs

Average Volume

1,608,561 shs

Market Capitalization

$405.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.08